Physician profile
Flor Rivera
NPI 1336802115
$2,587.05
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $488 · 2023: $1,410 · 2024: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004 · Education: $94.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.02 |
| Education | $94.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $400.66 | 2022-2024 | Breztri, Fasenra, Airsupra |
| Mylan Specialty L.P. | $369.34 | 2022-2024 | Yupelri |
| Glaxosmithkline, LLC. | $365.32 | 2022-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Baxter Healthcare | $179.57 | 2022-2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $177.66 | 2023-2024 | Glassia |
| Amgen INC. | $166.71 | 2023-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.71 | 2022-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Inspire Medical Systems, INC. | $144.00 | 2023-2024 | Inspire |
| United Therapeutics Corporation | $124.79 | 2022-2024 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $81.77 | 2023-2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $76.82 | 2023-2024 | Dupixent |
| Insmed, INC. | $59.10 | 2023 | Arikayce |
| Pulmonx Corporation | $45.12 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Ani Pharmaceuticals, INC. | $33.34 | 2024 | Purified Cortrophin Gel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.24 | 2023-2024 | Keytruda |
| Fisher & Paykel Healthcare INC | $21.59 | 2022 | |
| Genzyme Corporation | $20.17 | 2023 | |
| Phadia US INC. | $16.44 | 2023 | Immunocap |
| Electromed, INC. | $12.75 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flor Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.